Novo Holdings Leads $100 Million Series C Financing of Asceneuron to Advance Groundbreaking Therapy for Alzheimer's Disease
Novo Holdings Leads $100 Million Series C Financing of Asceneuron to Advance Groundbreaking Therapy for Alzheimer's Disease
- Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer's disease
- Alzheimer's disease is an area of very high unmet medical need with a lack of oral disease modifying therapies
- Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings will join Asceneuron Board of Directors
- 资金将用于推进ASN51领先资产，这是一种口服小分子OGA抑制剂，用于治疗阿尔茨海默病的二期临床实验发展。
- 阿尔茨海默病是医疗需求非常高，缺乏口服疾病修复疗法的领域。
- Naveed Siddiqi，Venture Investments的高级合伙人，Novo Holdings将加入Asceneuron董事会。
COPENHAGEN, Denmark, July 16, 2024 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announces it led a $100 million Series C Financing in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a driver of neurodegenerative disease. The financing will be used to advance Asceneuron's lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer's disease.
丹麦哥本哈根，2024年7月16日 /新华社/ --领先的生命科学投资者Novo Holdings今日宣布，其领导的1亿美元C轮融资投资Asceneuron，一家临床阶段的生物技术公司，开发针对tau蛋白聚集的小分子药物，这是神经退行性疾病的驱动因素。资金将用于将Asceneuron的领先资产ASN51推进阿尔茨海默病的二期临床实验。
ASN51 is an oral small molecule drug designed to inhibit OGA, an enzyme implicated in tau protein aggregation. By preventing the aggregation of tau proteins, ASN51 aims to slow the progression of Alzheimer's disease. OGA inhibition has also shown promising potential to prevent the aggregation of proteins that are central to other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis.
ASN51是口服小分子药物，设计用于抑制OGA，这是与tau蛋白聚集有关的一种酶。通过防止tau蛋白的聚集，ASN51旨在减缓阿尔茨海默病的进展。OGA的抑制还显示出潜在的前景，可以预防与其他神经退行性疾病，包括帕金森病和肌萎缩侧索硬化症有关的蛋白聚集。
ASN51's unique mode of action and convenient oral formulation make it an ideal therapy for patients with Alzheimer's disease. Asceneuron has completed five Phase 1 clinical trials, demonstrating complete central nervous system uptake and high OGA enzyme occupancy, indicating its potential for differentiation from its competitors. Asceneuron plans to initiate its first Phase 2 clinical study later this year.
ASN51独特的作用方式和方便的口服制剂使其成为阿尔茨海默病患者理想的疗法。Asceneuron已经完成了五项一期临床试验，证明了完全的中枢神经系统摄取和高OGA酶占用率，表明其在竞争对手中具有差异化的潜力。 Asceneuron计划于今年晚些时候启动其第一项二期临床研究。
Asceneuron has a seasoned leadership team and a world class Scientific Advisory Board of experts in neurodegenerative diseases.
Asceneuron拥有经验丰富的领导团队和世界一流的科学顾问委员会，专门从事神经退行性疾病领域的专家。
Naveed Siddiqi MD, Senior Partner, Venture Investments, Novo Holdings said: "Alzheimer's disease is undergoing a transformational moment. Millions are afflicted by this devastating disease and there are very few therapeutic options. Validated biomarkers are allowing for more focused and rapid development. We are now witnessing the approvals of the first disease modifying antibody based injectable therapies. Asceneuron's innovative oral small molecule drug targeting intracellular tau offers the potential for a paradigm shift in the way this neurodegenerative disease is treated."
Naveed Siddiqi，MD，Venture Investments的高级合伙人，Novo Holdings表示：“阿尔茨海默病正在经历转型时刻。数百万人饱受这种毁灭性疾病之苦，疗法极少。已验证的生物标志物使得选拔更集中、开发更快捷。我们现在正在见证首批基于抗体的疾病修复注射疗法的批准。 Asceneuron创新的口服小分子药物，针对细胞内tau的靶向提供了潜在的范式转变，可以治疗这种神经退行性疾病。”
In connection with the financing, Naveed Siddiqi will join the Asceneuron Board of Directors.
与融资有关，Naveed Siddiqi将加入Asceneuron董事会。
Barbara Angehrn Pavik, Chief Executive Officer of Asceneuron, commented: "This high caliber life science investor syndicate, led by Novo Holdings, further validates the potential of our OGA inhibitor pipeline and leadership in the field of tauopathies. We are excited to advance our lead asset ASN51 into Phase 2 clinical development, recognizing its potential to significantly expand treatment options for patients with Alzheimer's disease."
Asceneuron首席执行官Barbara Angehrn Pavik评论道：“这家由Novo Holdings领导的高素质生命科学投资者共同投资，进一步验证了我们OGA抑制剂管道的潜力和在tauopathies领域的领导地位。我们很高兴将我们的领导资产ASN51推进阿尔茨海默病的二期临床发展，认识到它在显著扩大阿尔茨海默病患者治疗选择方面的潜力。”
The financing was led by Novo Holdings, with additional new investment from EQT Life Sciences Dementia Fund, OrbiMed and SR One, alongside participation from existing investors, M Ventures and Sofinnova Partners.
该融资由Novo Holdings领导，EQt Life Sciences Dementia Fund，OrbiMed和SR One等新增投资者，以及现有投资者万Ventures和索芬诺瓦合伙人参加。
About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
关于Novo Holdings A/S
Novo Holdings是一家控股和投资公司，负责管理Novo Nordisk Foundation的资产和财富。Novo Holdings的目的是通过对Novo Nordisk Foundation的资产获得有吸引力的长期回报，从而改善人们的健康以及社会和地球的可持续性。
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health Investments and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
Novo Holdings是Novo Nordisk A/S和Novonesis A/S（Novozymes A/S）的控股股东，管理具有长期回报前景的投资组合。除了管理广泛的股票，债券，房地产，基础设施和私募股权资产组合外，Novo Holdings还是世界领先的生命科学投资者。通过其种子，创业，成长，亚洲，全球计划卫生投资和主要投资团队，Novo Holdings投资于生命科学公司的各个发展阶段。
As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. .
截至2023年末，Novo Holdings的总资产为eur 1490亿。
About Asceneuron
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The company's pipeline reflects its ambition and commitment to developing treatments for a wide range of neurodegenerative diseases. Asceneuron has two clinical-stage small molecule OGA inhibitors in development: ASN90 (licensed to Ferrer Pharmaceuticals) for the treatment of progressive supranuclear palsy (PSP) and a potential best-in-class molecule, ASN51, for Alzheimer's disease. The company is also planning to advance its pre-clinical development pipeline in Parkinson's disease, amyotrophic lateral sclerosis (ALS) and other neurodegenerative indications. Asceneuron is backed by a renowned syndicate of investors consisting of Alzheimer's Drug Discovery Foundation (ADDF), EQT Life Sciences Dementia Fund, GSK Equities Investments Limited, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners, M Ventures, Novo Holdings, OrbiMed, Sofinnova Partners and SR One. For more information, please visit .
关于Asceneuron
Asceneuron是一家临床阶段的生物技术公司，专注于开发口服可利用的治疗极需的神经退变性疾病。该公司的产品线反映了其开发治疗各种神经退变性疾病的野心和承诺。Asceneuron有两种处于临床阶段的小分子OGA抑制剂：ASN90（授权给Ferrer Pharmaceuticals）治疗渐进性核上性麻痹（PSP）和ASN51提供阿尔茨海默病最佳潜在分子。该公司还计划推进其帕金森病、肌萎缩侧索硬化症（ALS）和其他神经退行性疾病的临床前研究管道。Asceneuron得到阿尔茨海默病药物发现基金(ADDF)、EQt Life Sciences Dementia Fund、GSK Equities Investments Limited、Johnson & Johnson Innovation – JJDC、Inc. (JJDC)、Kurma Partners万 Venture，Novo Holdings，OrbiMed，索芬诺瓦合伙人和SR One的一流投资者的支持。有关更多信息，请访问。
SOURCE Novo Holdings
新威集团来源